Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Depreciation & Amortization (CF) of $337000.0 for Q1 2026, up 0.6% on a QoQ basis from $335000.0 in Q4 2025, and up 6.98% year-over-year from $315000.0 in Q1 2025.
Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $337000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 6.98% year-over-year to $337000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 9.79% YoY) and the FY2025 annual result came in at $1.3 million, up 7.01% from the prior year.
- Depreciation & Amortization (CF) was $337000.0 for Q1 2026 at Xeris Biopharma Holdings, up from $335000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $391000.0 in Q3 2023 and bottomed at $281000.0 in Q2 2024.
- A 5-year average of $339000.0 and a median of $337000.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slipped 27.2% — and 2025, when it increased 15.66%.
- Xeris Biopharma Holdings' Depreciation & Amortization (CF) stood at $366000.0 in 2022, then fell by 5.46% to $346000.0 in 2023, then declined by 9.54% to $313000.0 in 2024, then advanced by 7.03% to $335000.0 in 2025, then gained by 0.6% to $337000.0 in 2026.
- Business Quant data shows XERS's Depreciation & Amortization (CF) at $337000.0 in Q1 2026, $335000.0 in Q4 2025, and $338000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 337,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 337,000.00 |
| Mar 31, 2026 | 337,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Sep 30, 2025 | 338,000.00 |
| Sep 30, 2025 | 338,000.00 |
| Jun 30, 2025 | 325,000.00 |
| Jun 30, 2025 | 325,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | 326,000.00 |
| Mar 31, 2024 | 326,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Dec 31, 2023 | 346,000.00 |